High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages

  Soong, Derrick ^a   Haj, Reem ^a   Leung, Mova G ^a   Myers, Robert ^a   Higgins, Brian ^a   Myers, Jeff ^a   Rajagopal, Sudha ^a  

^a CREDIT VALLEY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; TAXOID;

ADJUVANT THERAPY; ANTIBIOTIC PROPHYLAXIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEVER; NEUTROPENIA; NOTE;

ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEUTROPENIA; TAXOIDS;

EID: 70349318435     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.0508     Document Type: Letter

References (8)

1. Jones SE, Holmes FA, O'Shaughnessy J, et al: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177-1183, 2009
2. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: myeloid growth factors, 2008 update. http://www.nccn.org/ professionals/physician-gls/ PDF/myeloid-growth.pdf
3. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006
4. Hughes WT, Armstrong D, Bodey GP, et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Inf Dis 34:730-751, 2002
5. Timmer-Bone JN, Tjan-Heijnen VC: Febrile neutropenia: Highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy in solid tumors. Anti-Cancer Drugs 17:881-889, 2006
6. Gafter-Gvili A, Fraser A, Paul M, et al: Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 4:CD004386, 2006
7. Pascoe J, Cullen M: The prevention of febrile neutropenia. Curr Opin Oncol 18:325-329, 2006
8. Tashiro H, Sagawa T, Okada K, et al: The safety of docetaxel with cyclophosphamide (TC) therapy as adjuvant chemotherapy for Japanese women with operable breast cancer [in Japanese]. Gan To Kagku Ryoho 34:393-396, 2007